FDA inspectors warned UCSF radiopharmaceutical facility that losing environmental control could pose a serious hazard to ...
DUBLIN, Nov. 10, 2025 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt") today announced the completion of the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables ...
The MarketWatch News Department was not involved in the creation of this content. Appointment Enhances Leadership Team with Deep Sterile Injectables Expertise and Ability to Drive the Company's Global ...
Some three months after merging, Mallinckrodt and Endo have taken the next step toward their joint future by spinning off their sterile injectables and generics businesses. With the transformation ...
Experienced Leadership Team with Deep Expertise Across Product Development, Manufacturing, Supply Chain, Quality, Compliance and Business Development and Seasoned Board of Directors ST. LOUIS, Nov. 10 ...
CEO Sigurdur Olafsson framed 2025 as “a defining year for Keenova,” citing the July merger with Endo, the November separation of Par Health, and the launch of Keenova as a “branded therapeutics ...
Appointment Enhances Leadership Team with Deep Sterile Injectables Expertise and Ability to Drive the Company's Global R&D Strategy and Execution ST. LOUIS, Jan. 12, 2026 /PRNewswire/ -- Par Health, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results